Strange IndiaStrange India

André et al. argue that classifying cancer solely on the basis of organ origin imperfectly informs tumour biology, and should be replaced by molecular profiling of tumour cells regardless of tissue type (Nature 626, 26–29; 2024). They reason that many therapies have shown efficacy across different cancers, and that clinical trials involving people with various cancers could accelerate drug development.

Competing Interests

Table of Contents

A.S. is on the advisory board or speaker’s bureau for Aignostics, Amgen, Astellas, Astra Zeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda and Thermo Fisher, and has research grants from Bayer, BMS, Chugai and Incyte. F.K. is co-founder of Aignostics and is on the advisory board or speaker’s bureau for Agilent, Aignostics, Astra Zeneca, BMS, Illumina, Merck, MSD, Pfizer, Roche and Sanofi.

Source link


Leave a Reply

Your email address will not be published. Required fields are marked *